EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Anticancer Activity of tin Oxide and Cerium-Doped Tin Oxide Nanoparticles Synthesized from Ipomoea Carnea Flower Extract

Manivannan Prasanth, Gurusamy Muruganandam, Krishnasamy Ravichandran, Gnanasekar Dayana Jeyaleela, Krishnasamy Shanthaseelan, Baskaran Pradhiba Priyadharshini

Biomedical and Biotechnology Research Journal (BBRJ) · 2022

DOI: 10.4103/bbrj.bbrj_100_22 ↗
AbstractBibliografische Angaben

Abstract

Background: The aim of the study is to investigate the anticancer potential of tin oxide (SnO 2 ) and different concentrations (2%, 4%, 6%, and 8%) of cerium-doped tin oxide nanoparticles (Ce-SnO 2 NPs) using Ipomoea carnea flower extract. The synthesized SnO 2 and different concentrations (2%, 4%, 6%, and 8%) of Ce-SnO 2 NPs was tested using a colorimetric-based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay against MCF-7 human breast cancer cell line cells. Methods: Collection and preparation of plant extract is preliminarily carried out followed by the synthesis of Undoped and Cerium doped Tin oxide nanoparticles is achieved by standard protocol along with that its anticancer activity also studied in this research. Results: The anticancer activity increased in direct proportion to the cerium-dopant concentration. Experimental results demonstrated that 8% Ce-SnO 2 NPs exhibited a potential anticancer effect compared with SnO 2 and other concentrations of Ce-SnO 2 NPs. Conclusion: According to the current findings, large-scale manufacturing of Ce-SnO 2 NPs might be recommended to have effective anticancer agents against breast cancer cell lines.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →